{"id":837394,"date":"2025-04-15T08:36:38","date_gmt":"2025-04-15T12:36:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/"},"modified":"2025-04-15T08:36:38","modified_gmt":"2025-04-15T12:36:38","slug":"neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/","title":{"rendered":"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8212; 176 Patents Issued and Outstanding Reinforces NeOnc\u2019s Competitive Position &#8212;<\/em>\n      <\/p>\n<p>CALABASAS, Calif., April  15, 2025  (GLOBE NEWSWIRE) &#8212; <strong>NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)<\/strong>, a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position.<\/p>\n<p>The Company\u2019s IP portfolio, covering its core pipeline, currently comprises 126 issued patents &#8211; 29 in the United States and 97 internationally; and 50 pending patents &#8211; 19 in the United States and 31 internationally.<\/p>\n<p>NeOnc\u2019s expanding IP portfolio reflects its innovation engine as well as its commitment to protecting and maximizing the commercial potential of its therapeutic candidates, globally. The Company\u2019s IP protections span all major pharmaceutical markets, including the U.S., European Union, China, Japan, Brazil, and Australia, as the Company advances its portfolio of next-generation therapeutics toward regulatory approval.<\/p>\n<p>\u201cIntellectual property is a cornerstone of our strategy, and the strength of our global patent portfolio reflects the depth of our innovation and the breadth of our ambition,\u201d said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. \u201cThis portfolio enhances our ability to protect our breakthroughs in oncology and neurology, including our intranasal drug delivery platform, and safeguards our proprietary capability to bio-conjugate existing standard-of-care treatments like TMZ. Together, these protections ensure a strong foundation for long-term value creation for shareholders and life-changing solutions for patients.\u201d<\/p>\n<p>NeOnc\u2019s lead programs \u2014 including NEO100, NEO212, NEO214, and NEO400 \u2014 are protected by extensive patent coverage, notably:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>NEO100<\/strong>, ultrapure perillyl alcohol, which is covered by eight U.S. patents expiring between 2031 and 2036, with potential extensions via the FDA\u2019s patent term extension program and additional exclusivity through NEO100\u2019s Orphan Drug Designation.<\/li>\n<li>\n          <strong>NEO212 and NEO214<\/strong>, structurally unique perillyl alcohol conjugates, which benefit from Orange Book eligibility and new chemical entity data exclusivity provisions post-approval.<\/li>\n<li>\n          <strong>NEO400<\/strong>, a topical anticancer agent, that recently has secured broad patent coverage in Europe, with similar filings underway globally.<\/li>\n<li>Additionally, the Company holds key patents for the use of its compounds in permeabilizing the blood-brain barrier, with protections extending into 2039.<\/li>\n<\/ul>\n<p>\u201cOur mission is to bring paradigm-shifting therapies to patients with some of the most challenging conditions, and our growing patent estate gives us the platform to do just that,\u201d said Dr. Thomas Chen, CEO of NeOnc Technologies. \u201cWe will continue to invest aggressively in IP as we advance toward clinical and regulatory milestones across our pipeline.\u201d<\/p>\n<p>\n        <strong>ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.<\/strong><br \/>\n        <br \/>NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company\u2019s NEO\u2122 drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc\u2019s NEO100\u2122 and NEO212\u2122 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.<\/p>\n<p>For more about NeOnc and its pioneering technology, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6skuANntlRE-MP6SnbZOrbLdbx9PI38Uas9DTGe-vaFRKpileNF8tf4HlzyZqNa9S0Lrk5YRYXAv7n9eTCUXpw==\" rel=\"nofollow\" target=\"_blank\"><u>neonc.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Important Cautions Regarding Forward Looking Statements <\/strong><br \/>\n        <br \/>All statements other than statements of historical facts included in this press release are \u201cforward-looking statements\u201d (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as \u201cprojected,\u201d \u201cexpect,\u201d \u201cpossibility\u201d and \u201canticipate,\u201d or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.<\/p>\n<p>\u201cNEO100\u201d is a registered trademark of NeOnc Technologies Holdings, Inc.<\/p>\n<p>\n        <strong>Company Contact: <\/strong><br \/>\n        <br \/>Patrick Walters<br \/>Chief Operations Officer<br \/>NeOnc Technologies Holdings, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UD5xqVMYfGWLAZgG4mB6nUTo19X4GQ6oMNPQVNly_WOnMgCd1zfETt88MDuQ0MYLEe5yhAu4oMPPpLsF5I4nsw==\" rel=\"nofollow\" target=\"_blank\"><u>info@neonc.com<\/u><\/a><\/p>\n<p>\n        <strong>Investor Relations: <\/strong><br \/>\n        <br \/>Roger Pondel \/ Laurie Berman<br \/>PondelWilkinson Inc.<br \/>(310) 279-5980<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7xcSa5F2nsfEdUHSzi8nqcu3fU0L7odcAXTO-GFY9GucABoK7bjqeiBg8h0IjLaG30Qd6GZSYJGGOUHBe9Ta1VghzKqiwXKnn_wh9a-EdOo=\" rel=\"nofollow\" target=\"_blank\"><u>rpondel@pondel.com<\/u><\/a>\/<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d2XZ41pgTk2NrlT5UdREuBhA09IO2S9knBhYbmFcT-bAJtr4ZGZ7ZYcvYeQnK3lE69bb90SCyV_oa4qSHWjB3ExgbLCmtjhXtF633aD2c2U=\" rel=\"nofollow\" target=\"_blank\"><u>lberman@pondel.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGFhOGE5ZWMtMWMxMS00MmI3LTg5OTEtNWE4NGVhMDFlNmU0LTEyNjgzODctMjAyNS0wNC0xNS1lbg==\/tiny\/NeOnc-Technologies-Holdings-In.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; 176 Patents Issued and Outstanding Reinforces NeOnc\u2019s Competitive Position &#8212; CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company\u2019s IP portfolio, covering its core pipeline, currently comprises 126 issued patents &#8211; 29 in the United States and 97 internationally; and 50 pending patents &#8211; 19 in the United States and 31 internationally. NeOnc\u2019s expanding IP portfolio reflects its innovation engine as well as its commitment to protecting and maximizing the commercial potential of its therapeutic candidates, globally. The Company\u2019s IP protections span all major pharmaceutical markets, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837394","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; 176 Patents Issued and Outstanding Reinforces NeOnc\u2019s Competitive Position &#8212; CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company\u2019s IP portfolio, covering its core pipeline, currently comprises 126 issued patents &#8211; 29 in the United States and 97 internationally; and 50 pending patents &#8211; 19 in the United States and 31 internationally. NeOnc\u2019s expanding IP portfolio reflects its innovation engine as well as its commitment to protecting and maximizing the commercial potential of its therapeutic candidates, globally. The Company\u2019s IP protections span all major pharmaceutical markets, &hellip; Continue reading &quot;NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T12:36:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets\",\"datePublished\":\"2025-04-15T12:36:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/\"},\"wordCount\":813,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/\",\"name\":\"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=\",\"datePublished\":\"2025-04-15T12:36:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/","og_locale":"en_US","og_type":"article","og_title":"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets - Market Newsdesk","og_description":"&#8212; 176 Patents Issued and Outstanding Reinforces NeOnc\u2019s Competitive Position &#8212; CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company\u2019s IP portfolio, covering its core pipeline, currently comprises 126 issued patents &#8211; 29 in the United States and 97 internationally; and 50 pending patents &#8211; 19 in the United States and 31 internationally. NeOnc\u2019s expanding IP portfolio reflects its innovation engine as well as its commitment to protecting and maximizing the commercial potential of its therapeutic candidates, globally. The Company\u2019s IP protections span all major pharmaceutical markets, &hellip; Continue reading \"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-15T12:36:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets","datePublished":"2025-04-15T12:36:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/"},"wordCount":813,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/","name":"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=","datePublished":"2025-04-15T12:36:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjIzNiM2ODY2MTQ5IzIyNTY4Mzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-global-patent-portfolio-covers-core-pipeline-across-all-major-pharmaceutical-markets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeOnc Technologies Global Patent Portfolio\u00a0Covers Core Pipeline Across All Major Pharmaceutical Markets"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837394"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837394\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}